Crossmark

Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes

Published Print: 2020-11

Authors

Galli, Mattia

Angiolillo, Dominick J.
Funding

Funding for this research was provided by:

Daiichi-Sankyo

Merck

AstraZeneca

Bayer

Gilead Sciences

CSL Behring

Eisai

Eli Lilly and Company

Amgen
License Information

Text and Data Mining valid from 2020-11-01

Text and Data Mining valid from 2020-11-01
More Information

This article is maintained by: Elsevier

Article Title: Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes

Journal Title: Revista Española de Cardiología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rec.2020.05.003

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rec.2020.01.005

Content Type: article

Copyright: © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Document is current